Although our study has some methodological limitations, the data suggest that CEA as a classic biomarker with intrinsic activity on tumor cells and tumor microenvironment might predict therapeutic response towards anti-VEGF therapy in mCRC. The gene discussed is VEGFA; the disease is neoplasm.